AACR: 2 years in, Amgen fortifies Lumakras lung cancer data fortress for upcoming Mirati, Novartis KRAS battle

Amgen is busy building Lumakras’ case, taking advantage of an unexpectedly longer lead over KRAS rival Mirati Therapeutics.

Two years in, Lumakras’ data in previously treated KRAS G12C-mutated non-small cell lung cancer continued to look solid. The first-in-class KRAS inhibitor shrunk tumors in 40.7% patients, with the response lasting a median of 12.3 months, according to data presented at the American Association for Cancer Research (AACR) annual meeting.